graph EGM comparisons
nivolumab plus ipilimumabtitlenivolumab alonetitleIpilimumab (10 mg/kg)titlepembrolizumab alonetitleipilimumab alonetitlepembrolizumab (10mg/kg)titleipilimumab plus gp100titlerelatlimab plus nivolumabtitleatezolizumab plus SoCtitleatezolizumab plus cometinibtitlepembrolizumab plus SoCtitlenivolumab followed by ipilimumabtitlepembrolizumab (10mg/kg) 2 weekstitlepembrolizumab (2mg/kg)titletremelimumabtitleipilimumab plus SoCtitleinterferon alphatitleplacebotitleplacebo plus SoCtitleipilimumab followed by nivolumabtitledacarbazinetitleStandard of Care (SoC)titlegp100titleCheckMate 067 (N vs I ; all population), 2015 NCT01844505 mML - L1 - all population 316/315CheckMate 064, 2016 NCT01783938 mML - L1 - all population 68/70CheckMate 069 (all population), 2015 NCT01927419 mML - L1 - all population 95/47CheckMate 067 (NI vs I ; all population), 2015 NCT01844505 mML - L1 - all population 314/315CheckMate 067 (NI vs N) EXPLORATORY, 2015 NCT01844505 mML - L1 - all population 314/316RELATIVITY-047, 0 NCT03470922 mML - L1 - all population -9/-9A3671009, 2013 NCT00257205 mML - L1 - all population 328/327IMspire-150 (BRAF mutant), 2020 NCT02908672 mML - L1 - BRAF mutant 256/258CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 NCT01927419 mML - L1 - BRAF mutant 23/10IMspire-170, 2020 NCT03273153 mML - L1 - BRAF wild 222/224CheckMate 066, 2015 NCT01721772 mML - L1 - BRAF wild 210/208CheckMate 069 (BRAF wild type), 2015 NCT01927419 mML - L1 - BRAF wild 72/37Ascierto (ipi 10 vs 3 mg/kg), 2017 NCT01515189 mML - L2 - all population 365/362CA184-004, 2011 NCT00261365 mML - L2 - all population 40/42MDX010 Ipi vs gp100, 2010 NCT00094653 mML - L2 - all population 137/136MDX010 Ipi plus gp100 vs gp100, 2010 NCT00094653 mML - L2 - all population 403/136MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 NCT00094653 mML - L2 - all population 403/137CA184-024, 2011 NCT00324155 mML - L2 - all population 250/252CheckMate 037, 2015 NCT01721746 mML - L2 - all population 272/133KEYNOTE-006 (3 week), 2015 NCT01866319 mML - L2 - all population 277/278KEYNOTE-002 (10 mg/kg), 2015 NCT01704287 mML - L2 - all population 181/179KEYNOTE-006 (2 week), 2015 NCT01866319 mML - L2 - all population 279/278KEYNOTE-002 (2 mg/kg), 2015 NCT01704287 mML - L2 - all population 180/179KEYNOTE-022, 2019 NCT02130466 mML - L2 - BRAF mutant 60/60E1609 (ipi10), 2020 NCT01274338 mML - NA - all population 511/636EORTC 18071, 2015 NCT00636168 mML - NA - all population 475/476E1609 (ipi3), 2020 NCT01274338 mML - NA - all population 523/636CheckMate 238, 2017 NCT02388906 mML - NA - all population 453/453IMMUNED (N vs P ; all population), 2020 NCT02523313 mML - NA - all population 59/52IMMUNED (NI vs N) EXPLORATORY, 2020 NCT02523313 mML - NA - all population 56/59CheckMate 915, 0 NCT03068455 mML - NA - all population -9/-9IMMUNED (NI vs P ; all population), 2020 NCT02523313 mML - NA - all population 56/52KEYNOTE 054 (all population), 2018 NCT02362594 mML - NA - all population 514/505KEYNOTE 054 (PDL1>1%), 2018 NCT02362594 mML - NA - PDL1 positive 428/425

Pathology:  mML - L1 - all population;   mML - L1 - BRAF mutant;   mML - L1 - BRAF wild;   mML - L2 - all population;   mML - L2 - BRAF mutant;   mML - NA - all population;   mML - NA - PDL1 positive; 

mML - L1 - all populationmML - L1 - BRAF mutantmML - L1 - BRAF wildmML - L2 - all populationmML - L2 - BRAF mutantmML - NA - all populationmML - NA - PDL1 positive
CheckMate 067 (N vs I ; all population), 2015CheckMate 064, 2016CheckMate 069 (all population), 2015CheckMate 067 (NI vs I ; all population), 2015CheckMate 067 (NI vs N) EXPLORATORY, 2015RELATIVITY-047, 0A3671009, 2013IMspire-150 (BRAF mutant), 2020CheckMate 069 (BRAF mutant) EXPLORATORY, 2015IMspire-170, 2020CheckMate 066, 2015CheckMate 069 (BRAF wild type), 2015Ascierto (ipi 10 vs 3 mg/kg), 2017CA184-004, 2011MDX010 Ipi vs gp100, 2010MDX010 Ipi plus gp100 vs gp100, 2010MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010CA184-024, 2011CheckMate 037, 2015KEYNOTE-006 (3 week), 2015KEYNOTE-002 (10 mg/kg), 2015KEYNOTE-006 (2 week), 2015KEYNOTE-002 (2 mg/kg), 2015KEYNOTE-022, 2019E1609 (ipi10), 2020EORTC 18071, 2015E1609 (ipi3), 2020CheckMate 238, 2017IMMUNED (N vs P ; all population), 2020IMMUNED (NI vs N) EXPLORATORY, 2020CheckMate 915, 0IMMUNED (NI vs P ; all population), 2020KEYNOTE 054 (all population), 2018KEYNOTE 054 (PDL1>1%), 2018
nivolumab plus ipilimumab8T1T1T1T1T1T1T1T1
nivolumab alone5T1T0T0T1T1T1T1T0T0
Ipilimumab (10 mg/kg)4T1T1T1T1T0
pembrolizumab alone2T0T1T1
ipilimumab alone2T0T0T0T0T0T0T0T1T0T0T0T1
pembrolizumab (10mg/kg)2T1T1
ipilimumab plus gp1002T1T1
relatlimab plus nivolumab1T1
atezolizumab plus SoC1T1
atezolizumab plus cometinib1T1
pembrolizumab plus SoC1T1
nivolumab followed by ipilimumab1T1
pembrolizumab (10mg/kg) 2 weeks1T1
pembrolizumab (2mg/kg)1T1
tremelimumab1T1
ipilimumab plus SoC1T1
interferon alpha0T0T0
placebo0T0T0T0T0T0
placebo plus SoC0T0T0T0
ipilimumab followed by nivolumab0T0
dacarbazine0T0
Standard of Care (SoC)0T0T0T0T0
gp1000T0T0